Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

NCT04284488
terminatedphase_1

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

NCT04643405
completedphase_1

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

NCT03386526
completedphase_1

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

NCT03585322

Clinical Trials (4)

Showing 4 of 4 trials
NCT04284488Phase 1

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Terminated
NCT04643405Phase 1

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Terminated
NCT03386526Phase 1

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Completed
NCT03585322Phase 1

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4